ATP2B2 and breast carcinoma: We also evaluated the consequences of PMCA2 silencing on the proliferation of MDA-MB-231 breast cancer cells and their sensitivity to doxorubicin, an anthracycline chemotherapy frequently used to treat breast cancer.